Editorial May 2025 Trumps Trade Policies Implications for the Chemical and Pharmaceutical Industries

Rajiv Parikh

16 May 2025

President Donald Trump’s renewed trade agenda is poised to significantly impact the global chemical and pharmaceutical sectors. With a focus on tariffs, reshoring, and supply chain security, these policies are reshaping industry dynamics, influencing everything from raw material sourcing to international collaborations.

Chemical Industry: Navigating Tariffs and Supply Chain Disruptions

The chemical industry faces substantial challenges under the new trade policies. The introduction of a 10% baseline tariff on most global imports, coupled with a 25% tariff on goods from Canada and Mexico, has disrupted established supply chains. These tariffs affect a broad spectrum of chemical products, including polyethylene, polypropylene, ethylene glycol, and methanol. U.S. producers, who have historically relied on exporting these surpluses, now confront retaliatory tariffs from key trading partners, threatening their competitiveness in international
markets.

Moreover, the U.S. chemical industry depends on imports for certain essential chemicals like benzene, melamine, and methyl ethyl ketone. Tariffs on these imports could lead to increased production costs, affecting downstream industries.

The fluorochemicals sector is particularly vulnerable. With the U.S. relying heavily on Mexico for fluorspar and hydrofluoric acid—key inputs for
refrigerants and fluoropolymers—tariffs on these imports could escalate costs and disrupt production.

Pharmaceutical Industry: Confronting Tariffs and Regulatory Challenges

The pharmaceutical sector is equally impacted by the new trade policies. Proposed tariffs of at least 25% on pharmaceutical products and active pharmaceutical ingredients (APIs) threaten to increase drug prices and disrupt supply chains. Given that a significant portion of APIs are sourced from countries like China and India, these tariffs could exacerbate existing drug shortages and elevate healthcare costs.

Furthermore, the U.S. has urged allies, such as the UK, to eliminate Chinese-made ingredients from medicines exported to the U.S., emphasizing
national security concerns. This move could compel pharmaceutical companies to overhaul their supply chains, potentially increasing production costs and affecting drug availability.

President Trump’s executive order aiming to align U.S. drug prices with those in lower-cost countries introduces additional complexities. While intended to reduce domestic drug prices, this policy could lead pharmaceutical companies to raise prices abroad to offset revenue losses, potentially straining international relations and impacting global drug affordability.

Key Chemicals and Pharmaceuticals Affected

Polyethylene and Polypropylene: Tariffs on these widely used plastics could increase costs for packaging and automotive industries.
Benzene, Melamine, and Methyl Ethyl Ketone: Essential chemicals with limited domestic production, making them susceptible to import tariffs.
Fluorspar and Hydrofluoric Acid: Critical for producing refrigerants and fluoropolymers; tariffs could disrupt supply chains.
Active Pharmaceutical Ingredients (APIs): Tariffs on APIs, primarily sourced from China and India, could lead to drug shortages and higher healthcare costs.

President Trump's trade policies are ushering in a period of significant transformation for the chemical and pharmaceutical industries. While aimed at bolstering domestic production and ensuring national security, these measures present challenges in terms of increased costs, supply chain disruptions, and regulatory complexities. Industry stakeholders must navigate this evolving landscape by fostering innovation, diversifying supply chains, and engaging in international collaborations to mitigate risks and seize emerging opportunities.